HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R J Gralla Selected Research

Vomiting

2/20242023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
1/2018Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
9/20162016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
7/2014Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
7/2014A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
5/2010Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
4/2006Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R J Gralla Research Topics

Disease

7Vomiting
02/2024 - 04/2006
7Nausea
02/2024 - 04/2006
4Neoplasms (Cancer)
01/2018 - 07/2014
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020 - 05/2001
1Disease Progression
01/2020
1Lung Neoplasms (Lung Cancer)
01/2020
1Renal Insufficiency (Renal Failure)
05/2001
1Squamous Cell Neoplasms (Squamous Cell Cancer)
05/2001
1Pancreatitis
05/2001
1Pleural Effusion (Pleural Effusions)
05/2001

Drug/Important Bio-Agent (IBA)

2Dexamethasone (Maxidex)FDA LinkGeneric
01/2018 - 07/2014
2AntiemeticsIBA
07/2014 - 04/2006
2Aprepitant (Emend)FDA Link
07/2014 - 04/2006
2Palonosetron (Aloxi)FDA Link
07/2014 - 07/2014
2Cisplatin (Platino)FDA LinkGeneric
07/2014 - 05/2001
2netupitantIBA
07/2014 - 07/2014
1AnthracyclinesIBA
01/2018
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2018
1Capsules (Microcapsules)IBA
01/2018
1N-nitrosoethylenethioureaIBA
07/2014
1Ondansetron (Zofran)FDA LinkGeneric
07/2014
1Adrenal Cortex Hormones (Corticosteroids)IBA
04/2006
1RetinoidsIBA
05/2001
1LigandsIBA
05/2001
1Triglycerides (Triacylglycerol)IBA
05/2001
1Bexarotene (LGD1069)FDA Link
05/2001
1Vinorelbine (Navelbine)FDA LinkGeneric
05/2001
1Retinoid X Receptors (Retinoid X Receptor)IBA
05/2001

Therapy/Procedure

8Drug Therapy (Chemotherapy)
02/2024 - 04/2006
3Radiotherapy
02/2024 - 05/2010
3Therapeutics
01/2020 - 05/2001
1Palliative Care (Palliative Therapy)
01/2020